Search

Your search keyword '"Susan Bengs"' showing total 2 results
Start Over Author "Susan Bengs" Publisher wiley
2 results on '"Susan Bengs"'

1. Metabolic Activity in Central Neural Structures of Patients With Myocardial Injury

Author

Michael Fiechter, Andrea Roggo, Ahmed Haider, Susan Bengs, Irene A. Burger, Monika Marędziak, Angela Portmann, Valerie Treyer, Anton S. Becker, Michael Messerli, Urs J. Mühlematter, Ken Kudura, Elia von Felten, Dominik C. Benz, Tobias A. Fuchs, Christoph Gräni, Aju P. Pazhenkottil, Ronny R. Buechel, Philipp A. Kaufmann, and Catherine Gebhard

Subjects
brainstem, caudate nucleus, corpus callosum, fluor‐18‐deoxyglucose positron emission tomography/computed tomography, myocardial perfusion imaging, nervous system, autonomic, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background Increasing evidence suggests a psychosomatic link between neural systems and the heart. In light of the growing burden of ischemic cardiovascular disease across the globe, a better understanding of heart‐brain interactions and their implications for cardiovascular treatment strategies is needed. Thus, we sought to investigate the interaction between myocardial injury and metabolic alterations in central neural areas in patients with suspected or known coronary artery disease. Methods and Results The association between resting metabolic activity in distinct neural structures and cardiac function was analyzed in 302 patients (aged 66.8±10.2 years; 70.9% men) undergoing fluor‐18‐deoxyglucose positron emission tomography and 99mTc‐tetrofosmin single‐photon emission computed tomography myocardial perfusion imaging. There was evidence for reduction of callosal, caudate, and brainstem fluor‐18‐deoxyglucose uptake in patients with impaired left ventricular ejection fraction (

Published
2019
Full Text
View/download PDF

2. β6-integrin serves as a novel serum tumor marker for colorectal carcinoma

Author

Philipp Busenhart, Stephan R. Vavricka, Marcel Halama, Henrik Petrowsky, Markus J. Mäkinen, Gerhard Rogler, Elisabeth Naschberger, Achim Weber, Céline Mamie, Silvia Lang, Michael Fried, Matthias Turina, Nathalie Britzen-Laurent, Pascal Frei, Anne Tuomisto, Stephanie Kasper, Jan Christoph, Eugenia Becker, Kirstin Atrott, Michael Scharl, Alexander Knuth, Lotta von Boehmer, Vera Schellerer, Michael Stürzl, Susan Bengs, Petr Hruz, Andreas Rickenbacher, Gisli Jenkins, Roland S. Croner, Marianne R. Spalinger, Dean Sheppard, and Tina Raselli

Subjects
Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, Colorectal cancer, Integrin, Disease, medicine.disease, digestive system diseases, 3. Good health, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Carcinoembryonic antigen, 030220 oncology & carcinogenesis, Internal medicine, Cohort, medicine, biology.protein, business, Prospective cohort study, neoplasms, Tumor marker
Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This study aims to identify β6 -integrin (ITGB6) as a novel serum tumor marker for diagnosis, prognosis, and surveillance of CRC. ITGB6 serum levels were validated in retro- and prospective CRC patient cohorts. ITGB6 serum levels were analyzed by ELISA. Using an initial cohort of 60 CRC patients, we found that ITGB6 is present in the serum of CRC, but not in non-CRC control patients. A cut-off of ≥2 ng/mL ITGB6 reveals 100% specificity for the presence of metastatic CRC. In an enlarged study cohort of 269 CRC patients, ITGB6 predicted the onset of metastatic disease and was associated with poor prognosis. Those data were confirmed in an independent, prospective cohort consisting of 40 CRC patients. To investigate whether ITGB6 can also be used for tumor surveillance, serum ITGB6-levels were assessed in 26 CRC patients, pre- and post-surgery, as well as during follow-up visits. After complete tumor resection, ITGB6 serum levels declined completely. During follow-up, a new rise in ITGB6 serum levels indicated tumor recurrence or the onset of new metastasis as confirmed by CT scan. ITGB6 was more accurate for prognosis of advanced CRC and for tumor surveillance as the established marker carcinoembryonic antigen (CEA). Our findings identify ITGB6 as a novel serum marker for diagnosis, prognosis, and surveillance of advanced CRC. This might essentially contribute to an optimized patient care.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results